documents
Data license: Public Domain (U.S. Government data) · Data source: Regulations.gov API (General Services Administration)
- perpetual_docket
- 1 = a standing/perpetual docket carrying a sentinel comment-end date (2050 or later; in practice 2099/2100 — agency guidance and exemption dockets that never close). 0 = an ordinary docket with a real deadline. NULL = no end date reported. The site's Open-for-Comment surface EXCLUDES perpetual_docket = 1 by default, so the site count and the bulk dump answer the same question differently: the dump is complete and includes them.
- comment_end_date
- The comment deadline as an Eastern (America/New_York) calendar date — CORRECTED in the 2026-09-06 daily snapshot (DataDawn queue #498): a snapshot whose _metadata row comment_end_date_grain reads 'eastern' carries the Eastern date; the pre-correction snapshots (through 2026-09-05) held the UTC-rolled day, one day LATE on every end-of-day close. Federal comment periods close at 11:59:59 PM Eastern and the source publishes that instant in UTC ('2026-08-26T03:59:59Z' = the 2026-08-25 deadline). Prefer comment_end_datetime for any arithmetic and convert it to America/New_York yourself; never 'subtract a day' from this column.
- comment_end_datetime
- AUTHORITATIVE. The full UTC instant of the comment deadline ('2026-08-26 03:59:59' == 11:59:59 PM Eastern on 2026-08-25). Convert to America/New_York for the official date; prefer this column over comment_end_date for anything computed.
93 rows where agency_id = "FDA" sorted by comment_end_datetime descending
This data as json, CSV (advanced)
agency_id 1
- FDA · 93 ✖
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | comment_end_datetime ▲ | perpetual_docket | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2015-N-3469-0001 | FDA | FDA-2015-N-3469 | Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket | Notice | Notice of Availability | 2015-10-27 | 2015 | 10 | 2015-10-27 | 2050-02-21 | 2050-02-22 04:59:59 | 1 | 2026-08-11 09:00:50 | 2015-27270 | 1 | 0 | 0900006481cf17b1 |
| FDA-2015-N-3534-0001 | FDA | FDA-2015-N-3534 | Bulk Drug Substances That Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket | Notice | Notice of Availability | 2015-10-27 | 2015 | 10 | 2015-10-27 | 2050-02-21 | 2050-02-22 04:59:59 | 1 | 2026-09-20 09:00:16 | 2015-27271 | 1 | 0 | 0900006481cf1710 |
| FDA-2011-N-0656-1315 | FDA | FDA-2011-N-0656 | Animal Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate | Notice | General Notice | 2026-05-11 | 2026 | 5 | 2026-05-11 | 2027-12-01 | 2027-12-02 04:59:59 | 0 | 2026-08-13 14:40:33 | 2026-09283 | 1 | 0 | 09000064b92cacd0 |
| FDA-2011-N-0655-0042 | FDA | FDA-2011-N-0655 | Animal Generic Drug User Fee Act; Stakeholder Consultation Meetings on the Animal Generic Drug User Fee Act Reauthorization; Request for Notification of Stakeholder Intent To Participate | Notice | Notice of Intent | 2026-05-11 | 2026 | 5 | 2026-05-11 | 2027-12-01 | 2027-12-02 04:59:59 | 0 | 2026-08-13 14:41:39 | 2026-09284 | 1 | 0 | 09000064b92cf91b |
| FDA-2011-N-0656-1314 | FDA | FDA-2011-N-0656 | Animal Drug User Fee Act; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-04-17 | 2026 | 4 | 2026-04-17 | 2027-12-01 | 2027-12-02 04:59:59 | 0 | 2026-08-20 09:01:12 | 2026-07498 | 1 | 0 | 09000064b928948d |
| FDA-2011-N-0655-0041 | FDA | FDA-2011-N-0655 | Animal Generic Drug User Fee Act; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-04-17 | 2026 | 4 | 2026-04-17 | 2027-12-01 | 2027-12-02 04:59:59 | 0 | 2026-10-29 09:00:22 | 2026-07497 | 1 | 0 | 09000064b928930a |
| FDA-2026-N-10832-0001 | FDA | FDA-2026-N-10832 | Infant Formula Nutrient Requirements | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2026-11-02 | 2026 | 11 | 2026-11-02 | 2027-03-02 | 2027-03-03 04:59:59 | 0 | 2026-11-22 10:00:39 | 2026-22273 | 1 | 0 | 09000064b96c7f91 |
| FDA-2024-D-2560-0035 | FDA | FDA-2024-D-2560 | Essential Drug Delivery Performance Characteristics for Devices Intended To Deliver Drugs and Biological Products; Revised Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-10-30 | 2026 | 10 | 2026-10-30 | 2027-01-28 | 2027-01-29 04:59:59 | 0 | 2026-10-30 18:34:42 | 2026-22203 | 1 | 0 | 09000064b96bf3a4 |
| FDA-2024-D-2560-0036 | FDA | FDA-2024-D-2560 | Essential Drug Delivery Performance Characteristics for Devices Intended to Deliver Drugs and Biological Products; Guidance for Industry - Draft Guidance | Other | Guidance | 2026-10-30 | 2026 | 10 | 2026-10-30 | 2027-01-28 | 2027-01-29 04:59:59 | 0 | 2026-11-03 10:00:32 | 1 | 0 | 09000064b96bf48f | |
| FDA-2026-N-7864-0001 | FDA | FDA-2026-N-7864 | Data Request (DR001): Use of the pH Cycling Test Model as a Testing Procedure for Fluoride Dentifrice Drug Products in Over-the-Counter (OTC) Monograph M021: Anticaries Drug Products for Over-the-Counter Human Use | Other | Request | 2026-07-28 | 2026 | 7 | 2026-07-28 | 2027-01-25 | 2027-01-26 04:59:59 | 0 | 2026-07-28 16:50:16 | 1 | 0 | 09000064b93c7444 | |
| FDA-2016-D-2343-3655 | FDA | FDA-2016-D-2343 | Hazard Analysis and Risk-Based Preventive Controls for Human Food; Draft Guidance for Industry; Availability | Proposed Rule | GDL Guidance | 2026-10-23 | 2026 | 10 | 2026-10-23 | 2027-01-21 | 2027-01-22 04:59:59 | 0 | 2026-10-24 09:01:08 | 2026-21669 | 1 | 0 | 09000064b969a7c0 |
| FDA-2016-D-2343-3656 | FDA | FDA-2016-D-2343 | Hazard Analysis and Risk-Based Preventive Controls for Human Food: Draft Guidance for Industry - Chapter 12: Control of Chemical Hazards | Other | Guidance | 2026-10-23 | 2026 | 10 | 2026-10-23 | 2027-01-21 | 2027-01-22 04:59:59 | 0 | 2026-11-18 10:01:00 | 1 | 0 | 09000064b969688b | |
| FDA-2025-N-2699-0001 | FDA | FDA-2025-N-2699 | Rulemaking To Provide That N-acetyl-L-cysteine Is Not Excluded From the Dietary Supplement Definition | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2026-11-17 | 2026 | 11 | 2026-11-17 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-18 10:01:08 | 2026-23351 | 1 | 0 | 09000064b972320a |
| FDA-2026-N-9703-0001 | FDA | FDA-2026-N-9703 | Salerno Pharmaceuticals; Proposal To Withdraw Approval of a New Drug Application for Flolipid Suspension, 20 Milligrams/5 Milliliters and 40 Milligrams/5 Milliliters; Opportunity for a Hearing | Notice | Notice of Opportunity of Hearing | 2026-11-18 | 2026 | 11 | 2026-11-18 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-18 19:49:27 | 2026-23413 | 1 | 0 | 09000064b97280d0 |
| FDA-2007-D-0369-2751 | FDA | FDA-2007-D-0369 | Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Notice | Notice of Availability | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 20:25:56 | 2026-23692 | 1 | 0 | 09000064b97314c7 |
| FDA-2007-D-0369-2752 | FDA | FDA-2007-D-0369 | PSG_219083 - Draft Guidance on Aficamten | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:37:55 | 1 | 0 | 09000064b972e48c | |
| FDA-2007-D-0369-2753 | FDA | FDA-2007-D-0369 | PSG_205636 - Draft Guidance on Albuterol Sulfate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:38:07 | 1 | 0 | 09000064b972e497 | |
| FDA-2007-D-0369-2754 | FDA | FDA-2007-D-0369 | PSG_016324 - Draft Guidance on Azathioprine | Other | Background Material | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:38:32 | 1 | 0 | 09000064b972e49d | |
| FDA-2007-D-0369-2755 | FDA | FDA-2007-D-0369 | PSG_219840 - Draft Guidance on Barium Sulfate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:38:48 | 1 | 0 | 09000064b972eea0 | |
| FDA-2007-D-0369-2756 | FDA | FDA-2007-D-0369 | PSG_219776 - Draft Guidance on Berotralstat Dihydrochloride | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:39:10 | 1 | 0 | 09000064b972eea2 | |
| FDA-2007-D-0369-2757 | FDA | FDA-2007-D-0369 | PSG_019845 - Draft Guidance on Betaxolol Hydrochloride | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:39:39 | 1 | 0 | 09000064b972f04c | |
| FDA-2007-D-0369-2758 | FDA | FDA-2007-D-0369 | PSG_219500 - Draft Guidance on Bumetanide | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:39:55 | 1 | 0 | 09000064b972f063 | |
| FDA-2007-D-0369-2759 | FDA | FDA-2007-D-0369 | PSG_215430 - Draft Guidance on Bupropion Hydrochloride; Dextromethorphan Hydrobromide | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:40:14 | 1 | 0 | 09000064b972f069 | |
| FDA-2007-D-0369-2760 | FDA | FDA-2007-D-0369 | PSG_008915 - Draft Guidance on Carbinoxamine Maleate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:40:30 | 1 | 0 | 09000064b972f09e | |
| FDA-2007-D-0369-2761 | FDA | FDA-2007-D-0369 | PSG_219155 - Draft Guidance on Delgocitinib | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:40:51 | 1 | 0 | 09000064b972f0a0 | |
| FDA-2007-D-0369-2762 | FDA | FDA-2007-D-0369 | PSG_215400 - Draft Guidance on Dihydroergotamine mesylate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:41:04 | 1 | 0 | 09000064b972f0a2 | |
| FDA-2007-D-0369-2763 | FDA | FDA-2007-D-0369 | PSG_020216 - Draft Guidance on Conjugated Estrogens | Other | Background Material | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:41:26 | 1 | 0 | 09000064b972f0a4 | |
| FDA-2007-D-0369-2764 | FDA | FDA-2007-D-0369 | PSG_218718 - Draft Guidance on Ethinyl Estradiol; Norethindrone Acetate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:41:40 | 1 | 0 | 09000064b972f0ab | |
| FDA-2007-D-0369-2765 | FDA | FDA-2007-D-0369 | PSG_022399 - Draft Guidance on Gabapentin Enacarbil | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:41:52 | 1 | 0 | 09000064b972f0ae | |
| FDA-2007-D-0369-2766 | FDA | FDA-2007-D-0369 | PSG_218881 - Draft Guidance on Imlunestrant Tosylate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:42:12 | 1 | 0 | 09000064b972f0b4 | |
| FDA-2007-D-0369-2767 | FDA | FDA-2007-D-0369 | PSG_208462 - Draft Guidance on Ixazomib Citrate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:42:24 | 1 | 0 | 09000064b972f0b7 | |
| FDA-2007-D-0369-2768 | FDA | FDA-2007-D-0369 | PSG_218879 - Draft Guidance on Lamotrigine | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:42:48 | 1 | 0 | 09000064b972f0bc | |
| FDA-2007-D-0369-2769 | FDA | FDA-2007-D-0369 | PSG_022074 - Draft Guidance on Lanreotide Acetate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:43:01 | 1 | 0 | 09000064b972f0c0 | |
| FDA-2007-D-0369-2770 | FDA | FDA-2007-D-0369 | PSG_206947 - Draft Guidance on Lenvatinib Mesylate | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:43:16 | 1 | 0 | 09000064b972f0c3 | |
| FDA-2007-D-0369-2771 | FDA | FDA-2007-D-0369 | PSG_021897 - Draft Guidance on Naltrexone | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:43:31 | 1 | 0 | 09000064b972f0c6 | |
| FDA-2007-D-0369-2772 | FDA | FDA-2007-D-0369 | PSG_218764 - Draft Guidance on Nerandomilast | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:43:45 | 1 | 0 | 09000064b972f0cb | |
| FDA-2007-D-0369-2773 | FDA | FDA-2007-D-0369 | PSG_018705 - Draft Guidance on Nitroglycerin | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:43:56 | 1 | 0 | 09000064b972f0cf | |
| FDA-2007-D-0369-2774 | FDA | FDA-2007-D-0369 | PSG_220934 - Draft Guidance on Orforglipron Calcium | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:44:13 | 1 | 0 | 09000064b972f0d4 | |
| FDA-2007-D-0369-2775 | FDA | FDA-2007-D-0369 | PSG_219070 - Draft Guidance on Paltusotine Hydrochloride | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:44:28 | 1 | 0 | 09000064b972f0d7 | |
| FDA-2007-D-0369-2776 | FDA | FDA-2007-D-0369 | PSG_009829 - Draft Guidance on Pyridostigmine Bromide | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:44:40 | 1 | 0 | 09000064b972f0dc | |
| FDA-2007-D-0369-2777 | FDA | FDA-2007-D-0369 | PSG_218436 - Draft Guidance on Remibrutinib | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:44:51 | 1 | 0 | 09000064b972f0e2 | |
| FDA-2007-D-0369-2778 | FDA | FDA-2007-D-0369 | PSG_219666 - Draft Guidance on Sepiapterin | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:45:24 | 1 | 0 | 09000064b972f0e7 | |
| FDA-2007-D-0369-2779 | FDA | FDA-2007-D-0369 | PSG_211527 - Draft Guidance on Trifarotene | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:45:35 | 1 | 0 | 09000064b972f0ef | |
| FDA-2007-D-0369-2780 | FDA | FDA-2007-D-0369 | PSG_219042 - Draft Guidance on Zongertinib | Other | Guidance | 2026-11-20 | 2026 | 11 | 2026-11-20 | 2027-01-19 | 2027-01-20 04:59:59 | 0 | 2026-11-20 21:46:14 | 1 | 0 | 09000064b972f0f6 | |
| FDA-2026-D-13432-0001 | FDA | FDA-2026-D-13432 | Early-Phase IND Protocol Recommendations for Solid Tumors; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-11-12 | 2026 | 11 | 2026-11-12 | 2027-01-11 | 2027-01-12 04:59:59 | 0 | 2026-11-12 20:07:17 | 2026-22970 | 1 | 0 | 09000064b970f43a |
| FDA-2026-N-12575-0001 | FDA | FDA-2026-N-12575 | Agency Information Collection Activities; Proposed Collection; Comment Request; Voluntary Qualified Importer Program | Notice | 60 Day Proposed Information Collection | 2026-11-12 | 2026 | 11 | 2026-11-12 | 2027-01-11 | 2027-01-12 04:59:59 | 0 | 2026-11-12 21:13:03 | 2026-22965 | 1 | 0 | 09000064b970f2e0 |
| FDA-2026-N-12508-0001 | FDA | FDA-2026-N-12508 | Hematology and Pathology Devices; Reclassification of Immunohistochemistry Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product | Proposed Rule | Request for Comment | 2026-11-12 | 2026 | 11 | 2026-11-12 | 2027-01-11 | 2027-01-12 04:59:59 | 0 | 2026-11-14 10:00:56 | 2026-23005 | 1 | 0 | 09000064b970f439 |
| FDA-2026-N-12280-0001 | FDA | FDA-2026-N-12280 | Agency Information Collection Activities; Proposed Collection; Comment Request; Veterinary Feed Directive | Notice | 60 Day Proposed Information Collection | 2026-11-12 | 2026 | 11 | 2026-11-12 | 2027-01-11 | 2027-01-12 04:59:59 | 0 | 2026-11-17 10:00:46 | 2026-22964 | 1 | 0 | 09000064b970f432 |
| FDA-2026-D-13432-0002 | FDA | FDA-2026-D-13432 | Early-Phase IND Protocol Recommendations for Solid Tumors; Guidance for Industry - Draft Guidance | Other | Guidance | 2026-11-12 | 2026 | 11 | 2026-11-12 | 2027-01-11 | 2027-01-12 04:59:59 | 0 | 2026-11-22 00:27:28 | 1 | 0 | 09000064b970fd58 | |
| FDA-2026-N-10742-0001 | FDA | FDA-2026-N-10742 | Patient-Level Data for Drugs and Biological Products Submissions Containing Real-World Data and Real-World Evidence; Request for Information | Notice | Requests for Information (RFI) | 2026-11-12 | 2026 | 11 | 2026-11-12 | 2027-01-11 | 2027-01-12 04:59:59 | 0 | 2026-11-22 10:00:42 | 2026-22996 | 1 | 0 | 09000064b970f47e |
| FDA-2026-N-13135-0002 | FDA | FDA-2026-N-13135 | Public Workshop: Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities | Other | Meeting | 2026-11-06 | 2026 | 11 | 2026-11-06 | 2027-01-05 | 2027-01-06 04:59:59 | 0 | 2026-11-06 22:14:03 | 1 | 0 | 09000064b96f2a4f | |
| FDA-2026-N-13135-0001 | FDA | FDA-2026-N-13135 | Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities: Discussion Paper and Request for Feedback | Other | Request | 2026-11-06 | 2026 | 11 | 2026-11-06 | 2027-01-05 | 2027-01-06 04:59:59 | 0 | 2026-11-19 10:01:08 | 1 | 0 | 09000064b96f2a4d | |
| FDA-2026-N-0131-0001 | FDA | FDA-2026-N-0131 | FDA Rare Disease Innovation Hub Future Programming; Request for Comments | Notice | Request for Comments | 2026-01-30 | 2026 | 1 | 2026-01-30 | 2026-12-31 | 2027-01-01 04:59:59 | 0 | 2026-10-27 09:00:12 | 2026-01903 | 1 | 0 | 09000064b91893ee |
| FDA-2026-D-6729-0001 | FDA | FDA-2026-D-6729 | U.S.-Origin Statements on Seafood; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-10-27 | 2026 | 10 | 2026-10-27 | 2026-12-28 | 2026-12-29 04:59:59 | 0 | 2026-10-28 09:00:50 | 2026-21838 | 1 | 0 | 09000064b96a7ffd |
| FDA-2023-N-3743-0004 | FDA | FDA-2023-N-3743 | Agency Information Collection Activities; Proposed Collection; Comment Request; Electronic Records; Electronic Signatures | Notice | 60 Day Proposed Information Collection | 2026-10-28 | 2026 | 10 | 2026-10-28 | 2026-12-28 | 2026-12-29 04:59:59 | 0 | 2026-10-28 18:13:57 | 2026-21908 | 1 | 0 | 09000064b96b00ae |
| FDA-2026-N-11301-0001 | FDA | FDA-2026-N-11301 | Agency Information Collection Activities; Proposed Collection; Comment Request; Application for Participation in Food and Drug Administration Fellowship and Traineeship Programs | Notice | 60 Day Proposed Information Collection | 2026-10-28 | 2026 | 10 | 2026-10-28 | 2026-12-28 | 2026-12-29 04:59:59 | 0 | 2026-10-28 18:17:19 | 2026-21914 | 1 | 0 | 09000064b96b0076 |
| FDA-2026-D-11188-0002 | FDA | FDA-2026-D-11188 | Electronic Submission Template for Investigational Device Exemption (IDE) Applications; Draft Guidance for Sponsors and Food and Drug Administration Staff | Other | Guidance | 2026-10-28 | 2026 | 10 | 2026-10-28 | 2026-12-28 | 2026-12-29 04:59:59 | 0 | 2026-10-31 09:01:08 | 1 | 0 | 09000064b96afd8f | |
| FDA-2026-D-6729-0002 | FDA | FDA-2026-D-6729 | U.S.-Origin Statements on Seafood: Guidance for Industry - Draft Guidance | Other | Guidance | 2026-10-27 | 2026 | 10 | 2026-10-27 | 2026-12-28 | 2026-12-29 04:59:59 | 0 | 2026-11-10 10:01:36 | 1 | 0 | 09000064b96a652d | |
| FDA-2026-N-11623-0001 | FDA | FDA-2026-N-11623 | Agency Information Collection Activities; Proposed Collection; Comment Request; Food and Drug Administration Rapid Response Surveys | Notice | 60 Day Proposed Information Collection | 2026-10-28 | 2026 | 10 | 2026-10-28 | 2026-12-28 | 2026-12-29 04:59:59 | 0 | 2026-11-10 10:01:37 | 2026-21912 | 1 | 0 | 09000064b96b00b1 |
| FDA-2026-N-11261-0001 | FDA | FDA-2026-N-11261 | Agency Information Collection Activities; Proposed Collection; Comment Request; Product Jurisdiction and Combination Products | Notice | 60 Day Proposed Information Collection | 2026-10-23 | 2026 | 10 | 2026-10-23 | 2026-12-22 | 2026-12-23 04:59:59 | 0 | 2026-10-23 18:44:26 | 2026-21713 | 1 | 0 | 09000064b969a84f |
| FDA-2026-N-11074-0001 | FDA | FDA-2026-N-11074 | Agency Information Collection Activities; Proposed Collection; Comment Request; Export Certificates for FDA Regulated Products | Notice | 60 Day Proposed Information Collection | 2026-10-23 | 2026 | 10 | 2026-10-23 | 2026-12-22 | 2026-12-23 04:59:59 | 0 | 2026-10-23 18:53:29 | 2026-21714 | 1 | 0 | 09000064b969a7fb |
| FDA-2025-D-4023-0001 | FDA | FDA-2025-D-4023 | Action Levels for Cadmium in Processed Food Intended for Babies and Young Children; Draft Guidance for Industry; Availability | Proposed Rule | GDL Guidance | 2026-10-23 | 2026 | 10 | 2026-10-23 | 2026-12-22 | 2026-12-23 04:59:59 | 0 | 2026-10-24 09:01:08 | 2026-21670 | 1 | 0 | 09000064b969a7c2 |
| FDA-2025-D-4023-0002 | FDA | FDA-2025-D-4023 | Action Levels for Cadmium in Processed Food Intended for Babies and Young Children: Draft Guidance for Industry; Draft Guidance | Other | Guidance | 2026-10-23 | 2026 | 10 | 2026-10-23 | 2026-12-22 | 2026-12-23 04:59:59 | 0 | 2026-11-20 10:00:21 | 1 | 0 | 09000064b9687f85 | |
| FDA-2026-N-3532-0005 | FDA | FDA-2026-N-3532 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Good Laboratory Practice Requirements for Nonclinical Laboratory Studies | Notice | 30 Day Proposed Information Collection | 2026-11-19 | 2026 | 11 | 2026-11-19 | 2026-12-21 | 2026-12-22 04:59:59 | 0 | 2026-11-19 19:15:11 | 2026-23541 | 1 | 0 | 09000064b972c82f |
| FDA-2026-N-3070-0010 | FDA | FDA-2026-N-3070 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; National Youth Tobacco Survey | Notice | 30 Day Proposed Information Collection | 2026-11-19 | 2026 | 11 | 2026-11-19 | 2026-12-21 | 2026-12-22 04:59:59 | 0 | 2026-11-19 19:31:57 | 2026-23542 | 1 | 0 | 09000064b972e113 |
| FDA-2026-N-12214-0001 | FDA | FDA-2026-N-12214 | Fit-for-Purpose Rare Disease Framework Initiative; Public Meeting; Request for Information and Comments | Notice | Request for Comments | 2026-10-16 | 2026 | 10 | 2026-10-16 | 2026-12-11 | 2026-12-12 04:59:59 | 0 | 2026-11-22 00:24:54 | 2026-21142 | 1 | 0 | 09000064b9676453 |
| FDA-2023-C-5679-0039 | FDA | FDA-2023-C-5679 | Color Additive Petition From Environmental Defense Fund et al.; Request To Amend the Color Additive Regulations To Remove the Solvents Ethylene Dichloride, Methylene Chloride, and Trichloroethylene | Rule | Final Rule | 2026-11-10 | 2026 | 11 | 2026-11-10 | 2026-12-10 | 2026-12-11 04:59:59 | 0 | 2026-11-12 10:01:38 | 2026-22865 | 1 | 0 | 09000064b9701131 |
| FDA-2026-C-3071-0006 | FDA | FDA-2026-C-3071 | Color Additive Petition From the International Association of Color Manufacturers; Request To Amend the Color Additive Regulations To Remove the Solvents Methylene Chloride, Trichloroethylene, and Ethylene Dichloride | Rule | Final Rule | 2026-11-10 | 2026 | 11 | 2026-11-10 | 2026-12-10 | 2026-12-11 04:59:59 | 0 | 2026-11-19 10:01:08 | 2026-22866 | 1 | 0 | 09000064b9701220 |
| FDA-2025-N-3262-0001 | FDA | FDA-2025-N-3262 | Substances Generally Recognized as Safe | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2026-08-11 | 2026 | 8 | 2026-08-11 | 2026-12-09 | 2026-12-10 04:59:59 | 0 | 2026-11-22 10:00:29 | 2026-16296 | 1 | 0 | 09000064b942ea41 |
| FDA-2020-E-1882-0005 | FDA | FDA-2020-E-1882 | Determination of Regulatory Review Period for Purposes of Patent Extension; MONOFERRIC | Notice | Determinations | 2026-10-09 | 2026 | 10 | 2026-10-09 | 2026-12-08 | 2026-12-09 04:59:59 | 0 | 2026-10-09 18:22:03 | 2026-20766 | 1 | 0 | 09000064b9657798 |
| FDA-2020-E-1892-0005 | FDA | FDA-2020-E-1892 | Determination of Regulatory Review Period for Purposes of Patent Extension; MONOFERRIC | Notice | Determinations | 2026-10-09 | 2026 | 10 | 2026-10-09 | 2026-12-08 | 2026-12-09 04:59:59 | 0 | 2026-10-09 18:23:55 | 2026-20766 | 1 | 0 | 09000064b965705e |
| FDA-2026-N-10605-0001 | FDA | FDA-2026-N-10605 | Agency Information Collection Activities; Proposed Collection; Comment Request; Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations | Notice | 60 Day Proposed Information Collection | 2026-10-08 | 2026 | 10 | 2026-10-08 | 2026-12-07 | 2026-12-08 04:59:59 | 0 | 2026-10-08 17:22:43 | 2026-20663 | 1 | 0 | 09000064b9651d3d |
| FDA-2026-N-5347-0001 | FDA | FDA-2026-N-5347 | Nonclinical Testing Terminology | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2026-09-22 | 2026 | 9 | 2026-09-22 | 2026-12-07 | 2026-12-08 04:59:59 | 0 | 2026-11-22 10:00:31 | 2026-19349 | 1 | 0 | 09000064b95ae769 |
| FDA-2026-N-5347-0002 | FDA | FDA-2026-N-5347 | Nonclinical Testing Terminology | Rule | Direct Final Rule | 2026-09-22 | 2026 | 9 | 2026-09-22 | 2026-12-07 | 2026-12-08 04:59:59 | 0 | 2026-11-22 10:00:31 | 2026-19350 | 1 | 0 | 09000064b95ae59d |
| FDA-2014-N-0053-1398 | FDA | FDA-2014-N-0053 | Challenges and Solutions in Lot-Level Food Traceability; Public Meeting | Notice | Public Meetings | 2026-10-09 | 2026 | 10 | 2026-10-09 | 2026-12-06 | 2026-12-07 04:59:59 | 0 | 2026-11-19 10:01:04 | 2026-20720 | 1 | 0 | 09000064b9653e73 |
| FDA-2026-D-8693-0002 | FDA | FDA-2026-D-8693 | Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Guidance for Industry; Draft Guidance for Industry | Other | Guidance | 2026-09-02 | 2026 | 9 | 2026-09-02 | 2026-12-01 | 2026-12-02 04:59:59 | 0 | 2026-09-03 00:56:30 | 1 | 0 | 09000064b94bc729 | |
| FDA-2026-D-8693-0001 | FDA | FDA-2026-D-8693 | Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-09-02 | 2026 | 9 | 2026-09-02 | 2026-12-01 | 2026-12-02 04:59:59 | 0 | 2026-09-03 18:40:25 | 2026-17961 | 1 | 0 | 09000064b94bf507 |
| FDA-2026-N-10132-0001 | FDA | FDA-2026-N-10132 | Agency Information Collection Activities; Proposed Collection; Comment Request; Protection of Human Subjects and Institutional Review Boards | Notice | 60 Day Proposed Information Collection | 2026-09-29 | 2026 | 9 | 2026-09-29 | 2026-11-30 | 2026-12-01 04:59:59 | 0 | 2026-10-23 09:00:38 | 2026-19849 | 1 | 0 | 09000064b95e7083 |
| FDA-2012-N-1021-0107 | FDA | FDA-2012-N-1021 | Instructions for Submitting Comments on the CDRH Fiscal Year 2027 Proposed Guidance Development | Other | Additional Information | 2026-10-01 | 2026 | 10 | 2026-10-01 | 2026-11-30 | 2026-12-01 04:59:59 | 0 | 2026-11-18 10:00:50 | 1 | 0 | 09000064b95fb842 | |
| FDA-2018-D-4533-2363 | FDA | FDA-2018-D-4533 | Compounding Animal Drugs From Bulk Drug Substances: Compounding Under CGMP in Federally-Registered Facilities; Draft Guidance for Industry; Availability; Agency Information Collection Activities; Proposed Collection; Comment Request | Notice | Notice of Availability | 2026-08-28 | 2026 | 8 | 2026-08-28 | 2026-11-27 | 2026-11-28 04:59:59 | 0 | 2026-08-28 16:31:49 | 2026-17580 | 1 | 0 | 09000064b94a6448 |
| FDA-2026-N-2742-0002 | FDA | FDA-2026-N-2742 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Color Additive Certification | Notice | 30 Day Proposed Information Collection | 2026-10-28 | 2026 | 10 | 2026-10-28 | 2026-11-27 | 2026-11-28 04:59:59 | 0 | 2026-10-28 17:35:55 | 2026-21913 | 1 | 0 | 09000064b96b0189 |
| FDA-2026-D-11783-0001 | FDA | FDA-2026-D-11783 | Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry; Availability | Notice | Notice of Availability | 2026-10-28 | 2026 | 10 | 2026-10-28 | 2026-11-27 | 2026-11-28 04:59:59 | 0 | 2026-10-28 17:49:35 | 2026-21954 | 1 | 0 | 09000064b96b00b6 |
| FDA-2018-D-4533-2364 | FDA | FDA-2018-D-4533 | Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities; Draft Guidance | Other | Guidance | 2026-08-28 | 2026 | 8 | 2026-08-28 | 2026-11-27 | 2026-11-28 04:59:59 | 0 | 2026-11-22 10:00:30 | 1 | 0 | 09000064b94a6e26 | |
| FDA-2026-D-11783-0002 | FDA | FDA-2026-D-11783 | Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management; Draft Guidance for Industry | Other | Guidance | 2026-10-28 | 2026 | 10 | 2026-10-28 | 2026-11-27 | 2026-11-28 04:59:59 | 0 | 2026-11-22 10:00:37 | 1 | 0 | 09000064b96a45c1 | |
| FDA-2015-N-3326-0056 | FDA | FDA-2015-N-3326 | Reauthorization of the Biosimilar User Fee Act; Public Meeting; Request for Comments | Notice | Request for Comments | 2026-09-25 | 2026 | 9 | 2026-09-25 | 2026-11-25 | 2026-11-26 04:59:59 | 0 | 2026-11-21 10:00:45 | 2026-19660 | 1 | 0 | 09000064b95c53b7 |
| FDA-2026-P-5995-0001 | FDA | FDA-2026-P-5995 | Suitability Petition from Hyman, Phelps, & McNamara P.C. | Other | Petition(s) | 2026-05-28 | 2026 | 5 | 2026-05-28 | 2026-11-24 | 2026-11-25 04:59:59 | 0 | 2026-09-29 15:44:43 | 1 | 0 | 09000064b92f59e1 | |
| FDA-2026-N-8563-0001 | FDA | FDA-2026-N-8563 | Regulatory Science Innovations Catalyzing Medical Device Development_Co-sponsored Public Meeting | Other | Meeting | 2026-08-06 | 2026 | 8 | 2026-08-06 | 2026-11-24 | 2026-11-25 04:59:59 | 0 | 2026-11-06 10:00:29 | 1 | 0 | 09000064b940e756 | |
| FDA-2026-N-9505-0002 | FDA | FDA-2026-N-9505 | Robotically-Assisted Surgical Devices - Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Draft Guidance | Other | Guidance | 2026-09-25 | 2026 | 9 | 2026-09-25 | 2026-11-24 | 2026-11-25 04:59:59 | 0 | 2026-11-21 10:00:46 | 1 | 0 | 09000064b95c6e19 | |
| FDA-2025-D-6952-0001 | FDA | FDA-2025-D-6952 | Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants; Draft Guidance for Industry; Availability | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2026-10-09 | 2026 | 10 | 2026-10-09 | 2026-11-23 | 2026-11-24 04:59:59 | 0 | 2026-10-09 17:58:29 | 2026-20721 | 1 | 0 | 09000064b96577e1 |
| FDA-2026-N-7130-0004 | FDA | FDA-2026-N-7130 | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Accreditation Scheme for Conformity Assessment Program | Notice | 30 Day Proposed Information Collection | 2026-10-23 | 2026 | 10 | 2026-10-23 | 2026-11-23 | 2026-11-24 04:59:59 | 0 | 2026-11-04 10:00:37 | 2026-21712 | 1 | 0 | 09000064b969a84d |
| FDA-2025-D-6952-0002 | FDA | FDA-2025-D-6952 | Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants: Guidance for Industry - Draft Guidance | Other | Guidance | 2026-10-09 | 2026 | 10 | 2026-10-09 | 2026-11-23 | 2026-11-24 04:59:59 | 0 | 2026-11-15 10:00:32 | 1 | 0 | 09000064b96574d6 | |
| FDA-2026-N-13038-0001 | FDA | FDA-2026-N-13038 | FDA/Office of Generic Drugs to Interested Parties; Request for Comments – Letter | Other | Letter(s) | 2026-10-23 | 2026 | 10 | 2026-10-23 | 2026-11-23 | 2026-11-24 04:59:59 | 0 | 2026-11-21 10:00:55 | 1 | 0 | 09000064b969a8da | |
| FDA-2026-N-10100-0001 | FDA | FDA-2026-N-10100 | FDA Scientific Public Workshop: Next-Generation Sequencing for Adventitious Agent Detection in Biologics | Notice | Meeting | 2026-08-31 | 2026 | 8 | 2026-09-23 | 2026-11-22 | 2026-11-23 04:59:59 | 0 | 2026-11-22 00:19:58 | 1 | 0 | 09000064b94b538f |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT,
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT, -- EASTERN calendar date of the close (queue #498 writer
-- fix, 2026-09-05; was the UTC-rolled day AFTER the ET
-- deadline before that). Display-grade only.
comment_end_datetime TEXT, -- full UTC close ("YYYY-MM-DD HH:MM:SS", queue #498):
-- the API expresses the 11:59:59 PM ET deadline as a UTC
-- datetime. AUTHORITATIVE: the predicate, days_left and
-- any timezone-aware render derive from THIS column.
perpetual_docket INTEGER, -- 1 = sentinel end date (queue #464); NULL = no end date
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date);
CREATE INDEX idx_docs_withdrawn ON documents(withdrawn);
CREATE INDEX idx_docs_perpetual ON documents(perpetual_docket);
document_type 4